title: Expression of CD30 as a biomarker to predict response to brentuximab vedotin.
authors.affiliation: Department of Pathology, Yale Cancer Center, Smilow Cancer Hospital of the Yale-New Haven Hospital, Yale University School of Medicine, New Haven, CT, USA.
authors.forename: Mina L
authors.initials: ML
authors.lastname: Xu
authors.affiliation: Division of Hematology, Yale Cancer Center, Smilow Cancer Hospital of the Yale-New Haven Hospital, Yale University School of Medicine, New Haven, CT, USA.
authors.forename: Carlos
authors.initials: C
authors.lastname: Acevedo-Gadea
authors.affiliation: Division of Hematology, Yale Cancer Center, Smilow Cancer Hospital of the Yale-New Haven Hospital, Yale University School of Medicine, New Haven, CT, USA.
authors.forename: Stuart
authors.initials: S
authors.lastname: Seropian
authors.affiliation: Department of Pathology, Yale Cancer Center, Smilow Cancer Hospital of the Yale-New Haven Hospital, Yale University School of Medicine, New Haven, CT, USA.
authors.forename: Samuel G
authors.initials: SG
authors.lastname: Katz
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism*; D000079963:Brentuximab Vedotin; D018450:Disease Progression; D005260:Female; D006689:Hodgkin Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage*; D017730:Ki-1 Antigen / Q000378:metabolism*; D016015:Logistic Models; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D018796:Immunoconjugates; D017730:Ki-1 Antigen; D000079963:Brentuximab Vedotin